glp 1 agonist risks GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Gastrointestinal effect and adverse effects
Description
DozioEVianelloEMalavazosAETacchiniLSchmitzGIacobellisGet alEpicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk
You can also contact your Blue Cross and Blue Shield of Kansas representative.
Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, et al
Bergman., A
Emerging antiobesity drugs in development Numerous novel treatments for obesity are currently in the pipeline, including triple agonists that target GLP-1, GIP, and glucagon receptors [26]
